There is limited data on high-intensity statin for secondary prevention in elderly acute myocardial infarction (AMI) patients above 75 years. This study aimed to assess the impact of high-intensity statin on 3-year outcomes in elderly AMI patients (> 75 years) who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES). From the Korea AMI registry (KAMIR)-National Institutes of Health (NIH), 2,063 elderly patients were divided into three groups based on statin therapy at discharge: high-intensity statin group (n = 521), low/moderate-intensity statin group (n = 1,419), and no statin group (n = 123). The primary endpoint was the 3-year composite of cardiac death and recurrent myocardial infarction (MI). The high-intensity statin group had a similar primary endpoint incidence compared to the low/moderate-intensity statin group (11.5% vs. 12.5%; aHR: 1.053; 95% CI: 0.780–1.423; P = 0.739), but a significantly lower incidence compared to the no statin group (11.5% vs. 22.0%; aHR: 2.433; 95% CI: 1.377–4.298; P = 0.002). Major adverse cardiac events were lower in the high-intensity statin group compared to the no statin group but similar to the low/moderate-intensity statin group. High-intensity statin significantly reduced 3-year outcomes in elderly AMI patients after PCI compared to no statin, with similar benefits to low/moderate-intensity statin.
Her et al. (2025) studied this question.